ALK rearrangements have generally been reported to be mutually exclusive with other driver alterations in NSCLC such as EGFR and KRAS mutations, although few studies have shown that they can coexist [30,31,32]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.